Medical/Pharmaceuticals

South Korean Mental Tech Startup DoctorPresso Publishes Study to Detect Depression from User-Generated Diary test data in International Journal

SEOUL, South Korea, Oct. 21, 2024 /PRNewswire/ -- Doctorpresso's study to detect depression from user-generated diary text data was published in the September 2024 issue of the Journal of Medical Internet Research (JMIR) in recognition of its excellence. JMIR noted the "new approach of Doctorpress...

2024-10-22 09:08 2425

A Comprehensive Introduction of the oneClick+ antigen platform

SHANGHAI, Oct. 21, 2024 /PRNewswire/ -- Sanyou Bio provides oneClick+ antigen one-stop solution, from antigen analysis to personalized preparation, to help tumor immunotherapy research and development. oneClick+ antigen platform is designed to provide high-quality annotation-related protein seque...

2024-10-22 03:00 1780

Datasea Announces the Closing of a $4.0 Million Private Offering, Primarily Funded by the Company's CEO and Director

BEIJING, Oct. 21, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based digital technology company focused on innovative high-tech acoustics and 5G AI multimodal digital technology, today announced that, as ofOctober 15, 2024, the Company closed its Regulati...

2024-10-21 21:30 3526

Mediso introduces true theranostic TheraMAX SPECT/CT

HAMBURG, Germany, Oct. 21, 2024 /PRNewswire/ -- Mediso is unveiling its new AnyScan® TRIO SPECT/CT, TheraMAX* scanner at the annual meeting of European Association of Nuclear Medicine (EANM). The first global installation of the A...

2024-10-21 16:00 1622

Great Bay Bio Intelligent Drug Development Ecosystem Officially Launched

HONG KONG, Oct. 20, 2024 /PRNewswire/ -- On October 18th, the new product launch event hosted by Great Bay Bio (hereinafter referred to as "GBB") was successfully held in Suzhou, where industry players gathered to celebrate the feast of technological innovation. At the event, GBB announced the of...

2024-10-21 13:57 1792

MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum

SAN FRANCISCO, Oct. 18, 2024 /PRNewswire/ -- Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These development programs offer new potentials for the future tre...

2024-10-18 22:09 2172

Neurophet to host Symposium featuring renowned expert in Alzheimer's disease treatment from the U.S.

- Invited Neurophet's scientific advisor Stephen Salloway, professor of Neurology at Brown Medical School as guest speaker - Shared latest insights on brain image analysis used for prescription of Alzheimer's disease treatments such as 'Leqembi' and 'Kisunla' SEOUL, South Korea, Oct. 18, 2024 /P...

2024-10-18 21:00 3354

LaNova Medicines Announces Initiation of Phase 1 Clinical Trial of Anti-PD-1/VEGF Bispecific Antibody LM-299 and Completion of $42 Million Series C1 Financing

* Phase 1 trial of LM-299, an anti-PD-1/VEGF BsAb, initiated in China for advanced solid tumors following promising preclinical results demonstrating strong inhibition of tumor growth and well-tolerated safety profile * IND for LM-299 in the US expected to be submitted in the second half of 20...

2024-10-18 18:00 2338

111 to Announce Third Quarter 2024 Unaudited Financial Results on November 28, 2024 - Conference Call to Follow

SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will repor...

2024-10-18 17:00 3505

Ping An Health Upgrades Chronic Disease Management Services with Significant Results in Digital Weight Management Program

HONG KONG and SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- The Weight Management and Public Health Action Conference, hosted by the National Center for Chronic and Noncommunicable Disease Control and Prevention ("NCNCD") and its affiliated institution, the Binhai Institute for Chronic Disease Control ...

2024-10-18 12:13 3769

Exclusive Interview with Lang Guojun, founder of Sanyou Bio: The Key to Breaking the Bottleneck of New Drug Innovation--The Past and Future of the Super-Trillion Molecule Library

SHANGHAI, Oct. 17, 2024 /PRNewswire/ -- In the ninth year since the establishment of Sanyou Bio, Lang Guojun believes that the time is perfect to unveil the world's largest super-trillion molecule library. During the interview with Tongxieyi, he frankly and confidently expressed, "Nine years of ...

2024-10-17 22:00 1762

Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted

SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ -- On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 tablets, a Class 1 innovative drug for the treatment of t...

2024-10-17 21:38 2477

Amplo Biotechnology Announces Three Presentations at the European Society of Gene and Cell Therapy 31st Annual Congress

SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Amplo Biotechnology, a biotechnology company developing genetic medicines for the treatment of neuromuscular diseases, announced the presentation of three posters at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, taking place f...

2024-10-17 18:39 1571

KIND Announces Late-Breaking Abstract Accepted for Presentation on AND017 Clinical Trials to Treat Anemia in Chronic Kidney Disease (CKD) at ASN - Kidney Week 2024

SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the late-br...

2024-10-17 15:44 1706

EmeTerm Smart and HeadaTerm 2 Achieve Health Canada MDL Certification

VANCOUVER, BC, Oct. 16, 2024 /PRNewswire/ -- WAT Medical Enterprise proudly announces a significant achievement: both EmeTerm Smart and HeadaTerm 2 have received Medical Device Licences (MDL) from Health Canada. EmeTerm Smart was certified onAugust 12, 2024, followed by HeadaTerm 2 on September 2...

2024-10-16 21:30 1815

Copper-67 SAR-bisPSMA updates

SYDNEY, Oct. 16, 2024 /PRNewswire/ --  HIGHLIGHTS Cohort 4 - SECuRE Trial * The third participant of cohort 4 (multi-dose) of the SECuRE trial1 has now completed the Dose Limiting Toxicity (DLT) period after a second dose of 12GBq of67Cu-SAR-bisPSMA, following on from the announcement dated 1...

2024-10-16 21:03 3162

IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer

HONG KONG, Oct. 16, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK)  (" Akeso", the "Company" ) announced positive results in progression-free survival (PFS) and overall survival (OS) from its Phase 3 clinical study (COMPASSION-16/AK104-303). This study evaluated the efficacy of its independently...

2024-10-16 19:02 1846

TenNor Announces More than 300 Million RMB Financing to Support Development and Commercialization of Late-Stage Assets Including Rifasutenizol for Heliobacter pylori Infections

SUZHOU, China, Oct. 16, 2024 /PRNewswire/ -- TenNor Therapeutics, a clinical stage company dedicated to developing new therapies to address unmet needs in infectious diseases, announced today the initial closing of a Series E financing round for more than300 million RMB. New investor AMR Action F...

2024-10-16 18:00 2330

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

PISCATAWAY, N.J., Oct. 16, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading sc...

2024-10-16 17:43 1740

SONIRE's HIFU Therapy System Designated as Breakthrough Device by FDA

TOKYO, Oct. 16, 2024 /PRNewswire/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based inTokyo, Japan, announces that its self-developed next-generation HIFU (High-Intensity Focused Ultrasound) therapy system (development code: Suizenji) has been designated as a breakthrough ...

2024-10-16 14:00 1762
1 ... 71727374757677 ... 251